Download video

Lec 2. Pharmacokinetics - Bioavailability pharmacology | Factors affecting bioavailability

146 views

Physiology Open

4 weeks ago

Lec 2. Pharmacokinetics - Bioavailability pharmacology | Factors affecting bioavailability

Lec 2. Pharmacokinetics - Bioavailability pharmacology | Factors affecting bioavailability

Lec 2. Pharmacokinetics - Bioavailability pharmacology | Factors affecting bioavailability
14:46
Lec 2. Pharmacokinetics - Bioavailability pharmacology | Factors affecting bioavailability
by Physiology Open
Lec 5 : Pharmacokinetics : Drug Elimination kinetics mbbs 2nd year
20:16
Lec 5 : Pharmacokinetics : Drug Elimination kinetics mbbs 2nd year
by Physiology Open
Pharmacokinetics: Pharmacokinetics II
49:52
Pharmacokinetics: Pharmacokinetics II
by TeachMeAandP
Real-world efficacy of second-line cabozantinib in renal cell carcinoma
0:40
Real-world efficacy of second-line cabozantinib in renal cell carcinoma
by VJOncology
Comparing cabozantinib to other TKIs in metastatic renal cell carcinoma
0:33
Comparing cabozantinib to other TKIs in metastatic renal cell carcinoma
by VJOncology
BTK and PLCG2 mutations in CLL patients taking ibrutinib
2:41
BTK and PLCG2 mutations in CLL patients taking ibrutinib
by VJHemOnc – Video Journal of Hematology \& HemOnc
NKT2152, an oral HIF-2α inhibitor, in pre-treated advanced clear cell renal carcinoma
1:31
NKT2152, an oral HIF-2α inhibitor, in pre-treated advanced clear cell renal carcinoma
by VJOncology
Knock-off mechanism of Ca2+ permeation – Sobolevsky Lab
0:19
Knock-off mechanism of Ca2+ permeation – Sobolevsky Lab
by Sobolevsky Lab
Intracellular Ca2+ in Rhodnius prolixus Malpighian tubule
1:01
Intracellular Ca2+ in Rhodnius prolixus Malpighian tubule
by Juan Ianowski
Q2 2025 FDA New Drug Approvals
48:37
Q2 2025 FDA New Drug Approvals
by Medication Academy
Potency and Purity
5:24
Potency and Purity
by Pharma Learning In Depth
11. Investigate protein-level effect of a non-canonical transcript variant KIF2A:p.Gly478Arg (VUS)
8:29
11. Investigate protein-level effect of a non-canonical transcript variant KIF2A:p.Gly478Arg (VUS)
by Broad Institute
Potency and efficacy of PIP4K2 inhibitors in ALL: looking forward to first-in-human trials
0:52
Potency and efficacy of PIP4K2 inhibitors in ALL: looking forward to first-in-human trials
by VJHemOnc – Video Journal of Hematology \& HemOnc
Limitations of D2 Antagonist
2:04
Limitations of D2 Antagonist
by NEI Psychopharm
New Drug Approvals Inluriyo (imlunestrant), Palsonify (paltusotine), and Rhapsido (remibrutinib)
18:30
New Drug Approvals Inluriyo (imlunestrant), Palsonify (paltusotine), and Rhapsido (remibrutinib)
by Medication Academy
Histamine dihydrochloride and IL-2 for AML: impacts for relapse risk and survival
1:50
Histamine dihydrochloride and IL-2 for AML: impacts for relapse risk and survival
by VJHemOnc – Video Journal of Hematology \& HemOnc
Novel Treatment For CKD | B2 Adrenergic Receptor Agonists | ft. Dr. Josh Lipschutz
4:49
Novel Treatment For CKD | B2 Adrenergic Receptor Agonists | ft. Dr. Josh Lipschutz
by Santa Barbara Nutrients
CALQUENCE® (acalabrutinib) Patient Management \& Adherence - Bradley, NP
16:38
CALQUENCE® (acalabrutinib) Patient Management \& Adherence - Bradley, NP
by CALQUENCE (acalabrutinib)
Exploring Lamotrigine Mechanisms and Strategies for Effective Dose Titration
4:47
Exploring Lamotrigine Mechanisms and Strategies for Effective Dose Titration
by Psychopharmacology Institute
Part II - Aracidonic Acid Metabolites
8:38
Part II - Aracidonic Acid Metabolites
by Armando Hasudungan
Interim results from a Phase II trial of epcoritamab plus lenalidomide in treatment-naive FL
1:42
Interim results from a Phase II trial of epcoritamab plus lenalidomide in treatment-naive FL
by VJHemOnc – Video Journal of Hematology \& HemOnc
Regenerative Medicine and A Prophylactic Drug against SARS-CoV-2 Infection
19:24
Regenerative Medicine and A Prophylactic Drug against SARS-CoV-2 Infection
by Advanced Materials Congress Lectures
ELOQUENT-2 trial: Elotuzumab for relapsed or refractory multiple myeloma
2:04
ELOQUENT-2 trial: Elotuzumab for relapsed or refractory multiple myeloma
by VJHemOnc – Video Journal of Hematology \& HemOnc